Evidence map›Paper›PMID 39490335›Full record

ReviewSeminars in nuclear medicine2024

Update on PSMA-based Prostate Cancer Imaging.

Esther Mena, Liza Lindenberg, Peter L Choyke

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in nuclear medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Esther MenaMolecular Imaging Program. National Cancer Institute, NIH, Bethesda, MD. Electronic address: esther.menagonzalez@nih.gov.
Liza LindenbergMolecular Imaging Program. National Cancer Institute, NIH, Bethesda, MD.
Peter L ChoykeMolecular Imaging Program. National Cancer Institute, NIH, Bethesda, MD.

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Intramural NIH HHS ZIA BC010655
6 · The paper itself

Abstract

The increased use of prostate-specific membrane antigen (PSMA) based PET imaging for prostate cancer (Pca) detection has revolutionized the clinical management of Pca, with higher diagnostic sensitivity for extraprostatic disease and increasing clinical utility across different stages of the disease. The integration of PSMA PET imaging into clinical guidelines and consensus documents reflects its growing importance in the personalized management of Pca. This review of recent literature highlights the rapid evolution of PSMA PET into the mainstream of staging and restaging and the decreasing reliance on conventional imaging modalities. This comprehensive review serves as a resource for clinicians and researchers involved in the domains of Pca diagnosis and management.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIProstatic NeoplasmsHumansMalePositron-Emission TomographyAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase II

Identifiers

PMID39490335
PMCPMC11570338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.